2025

Information letter to healthcare professionals, overdose and risk of medication errors with the medicinal product EXOPON (paracetamol), solution for infusion, 10 mg/mL

Information letter addressed to healthcare professionals regarding the medicinal product Epadol Neo (omega-3 acid ethyl esters): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular disease or cardiovascular risk factors

Information letter for healthcare professionals on the dose-dependent increased risk of atrial fibrillation with the use of a medicinal product based on omega-3 acid ethyl esters in patients with cardiovascular diseases or risk factors. generated automatically

Informational letter to healthcare professionals, Amiodarone: reminder of the risks of treatment and the need for patient monitoring and follow-up

Patient reminder card for non-oncological indications of the medicinal product MABTHERA®

Informational letter addressed to healthcare professionals on the safety of the use of the medicinal products AVODART and DUODART. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

Information letter addressed to healthcare professionals on updated risk minimization measures for suicidal thoughts when using medicinal products containing finasteride and dutasteride, in particular recommendations on discontinuing treatment and seeking medical help. compiled automatically

Information letter to healthcare professionals regarding the medicinal product ANALGIN. Important information on minimizing the serious consequences of the known risk of agranulocytosis associated with the use of medicinal products containing metamizole

Informational letter to healthcare professionals on minimizing the serious consequences of the known risk of agranulocytosis when using medicinal products containing metamizole. Contains recommendations on informing patients about early symptoms, discontinuing treatment, and seeking immediate medical care. generated automatically

Informational letter to healthcare professionals. Important changes to the package insert of the medicinal products “SIMPONI®, solution for injection in a pre-filled pen with auto-injector 50 mg” and “SIMPONI®, solution for injection in a pre-filled pen with auto-injector 100 mg

Information letter to healthcare professionals on important changes to the package insert of a medicinal product in the form of a pre-filled pen with an autoinjector. The document reports identified safety problems (accidental needle sticks, bent needles, device malfunction) and updated rules for administering injections. generated automatically

Educational materials on the safe use of the medicinal product Xeljanz (tofacitinib)

Informational letter to healthcare professionals on updated recommendations for minimizing the risks of malignancies, serious cardiovascular events, infections, venous thromboembolism and mortality with the use of Janus kinase inhibitors. Contains general information on the safety issue, recommendations on dosing and patient examination. compiled automatically

Information letter to healthcare professionals regarding changes to the package leaflets of the medicinal products Ultracain® D-S and Ultracain® D-S Forte

Informational letter from the manufacturer to healthcare professionals on important safety changes in the instructions for medical use of two medicinal products that are at the approval stage in Ukraine. The updates to the sections “Special precautions for use” and “Interaction with other medicinal products” regarding use in various patient groups and associated risks are summarized. compiled automatically

Communication materials for healthcare professionals and patients on the safety of the medicinal product THIOCOLCHICOSIDE. Important information on the identified risk of aneuploidy/aneugenic effect (a risk factor for teratogenicity/embryotoxicity/spontaneous abortion, cancer, and male infertility) associated with the use of the medicinal product THIOCOLCHICOSIDE

Informational letter addressed to healthcare professionals on the safety of use of a medicinal product containing thiocolchicoside: a warning about the identified risk of aneuploidy/aneugenic effect and the associated risks of teratogenicity, embryotoxicity, spontaneous abortion, cancer and male infertility, as well as contraception requirements and restrictions on use. compiled automatically